Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Convertible Debt (2020 - 2025)

Apellis Pharmaceuticals has reported Convertible Debt over the past 6 years, most recently at $93.5 million for Q2 2025.

  • Quarterly results put Convertible Debt at $93.5 million for Q2 2025, changed 0.34% from a year ago — trailing twelve months through Jun 2025 was $93.5 million (changed 0.34% YoY), and the annual figure for FY2024 was $93.3 million, changed 0.33%.
  • Convertible Debt for Q2 2025 was $93.5 million at Apellis Pharmaceuticals, roughly flat from $93.4 million in the prior quarter.
  • Over the last five years, Convertible Debt for APLS hit a ceiling of $386.5 million in Q2 2021 and a floor of $92.7 million in Q3 2022.
  • Median Convertible Debt over the past 5 years was $93.3 million (2024), compared with a mean of $147.0 million.
  • Biggest five-year swings in Convertible Debt: soared 167.12% in 2021 and later plummeted 51.13% in 2022.
  • Apellis Pharmaceuticals' Convertible Debt stood at $189.0 million in 2021, then crashed by 50.94% to $92.7 million in 2022, then grew by 0.32% to $93.0 million in 2023, then increased by 0.33% to $93.3 million in 2024, then rose by 0.17% to $93.5 million in 2025.
  • The last three reported values for Convertible Debt were $93.5 million (Q2 2025), $93.4 million (Q1 2025), and $93.3 million (Q4 2024) per Business Quant data.